There are currently 165 clinical trials in Allentown, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including Lehigh Valley Hospital-Cedar Crest, LeHigh Valley Hospital, Lehigh Valley Health Network and Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: St. Luke's University Health Network, Allentown, Pennsylvania
Conditions: Heart Failure
Register for Updates
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
NCT04545502
Recruiting
The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice. Data will be collected both retrospectively and prospectively.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Lehigh Valley Hospital, Allentown, Pennsylvania
Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Register for Updates
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337
Recruiting
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Lehigh Valley Health Network, Allentown, Pennsylvania
Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Register for Updates
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
Recruiting
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Recruiting
This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
Gender:
All
Ages:
99 years and below
Trial Updated:
04/05/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Childhood Malignant Neoplasm
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
NCT04090424
Recruiting
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2024
Locations: Lehigh Valley Hospital and Health Network, Allentown, Pennsylvania
Conditions: Burns
Register for Updates
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
All
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Lehigh Valley Health Network, Allentown, Pennsylvania
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: Lehigh Center for Clinical Research, LLC, Allentown, Pennsylvania
Conditions: Generalized Anxiety Disorder
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
NCT05455606
Recruiting
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: The Heart Care Group, PC, Allentown, Pennsylvania
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates